Analytical performance of TruSight™ Oncology 500 ctDNA v2

Next-generation sequencing (NGS) based liquid biopsy is emerging as standard of care in oncology for comprehensive genomic profiling (CGP) of solid tumors. In this presentation we will showcase the analytical performance of TruSight™ Oncology 500 ctDNA version 2 (TSO 500 ctDNA v2, Illumina, San Diego, CA; Research Use Only), an NGS-based assay that utilizes the same gene panel as TSO 500 ctDNA. Its improved workflow reduces cfDNA input requirements, total turn-around time and hands-on time while still delivering all key biomarker data available from the TSO 500 gene panel.

 

Learning Objectives